Platform Enters New Era
The U.S. Food and Drug Administration has approved Moderna's mRNA based seasonal influenza vaccine, marking the first time a messenger RNA vaccine has received clearance for seasonal flu in the country. The approval extends mRNA technology well beyond its pandemic origins and shows that regulators are gaining confidence in the platform's ability to address common, recurring infectious diseases rather than just emergency health threats. It also reinforces a broader industry belief that mRNA can evolve from a crisis response tool into a lasting foundation for future vaccine development.
Technology Moves Beyond COVID
The vaccine, which will be sold under the name mFlusiva, received full approval for adults between 50 and 64 years old, while adults 65 and older were granted accelerated approval. Moderna has agreed to conduct an additional trial and submit further data for the older age group to confirm long term benefit. The approval was supported by a large late stage trial involving more than 40,000 adults aged 50 and above, in which the vaccine proved to be about 26.6% more effective than a standard dose flu shot already on the market. Separate data also showed that the vaccine produced a stronger antibody response compared with a widely used high dose flu vaccine from Sanofi in older adults. Unlike traditional flu vaccines that are largely produced using egg based methods, Moderna's shot relies on mRNA to prompt the body into generating its own flu antigens, a process that could allow quicker updates whenever circulating strains shift each season.
Competition Shifts Toward Platforms
This approval places Moderna in direct competition with established flu vaccine makers including Sanofi, GSK, CSL Seqirus, and AstraZeneca, all of whom currently rely on more conventional vaccine technology. Analysts do not expect the new shot to generate significant revenue until H2 2027, largely because Moderna missed the contracting window for the current flu season. Even so, some analysts have projected combined sales nearing $750 million by 2030 once the flu vaccine and a planned combination COVID + flu shot reach the market together. The company has been counting on these products to offset declining COVID vaccine revenue and to demonstrate that its mRNA platform has staying power well beyond the pandemic years.
Healthcare Innovation Accelerates
The road to this approval was not entirely smooth. Moderna withdrew its application for a combined COVID + flu vaccine last year after regulators asked for more evidence on the flu component, a decision that came during a period of unusually strict FDA scrutiny under previous agency leadership. That leadership has since changed, with new oversight working to rebuild trust between regulators and the industry. Despite these hurdles, this approval marks a real turning point for how vaccines get built going forward. Speed, adaptability, and the strength of the underlying platform are starting to matter just as much as raw efficacy numbers once did.
Whether mRNA can hold onto this momentum, or whether rivals catch up fast, is a story worth watching closely in the months ahead.